25.25
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA to present phase 2 data on uveal melanoma drug at ESMO By Investing.com - Investing.com South Africa
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma - Yahoo Finance
What drives IDEAYA Biosciences Inc. stock priceRobust financial gains - Autocar Professional
What analysts say about IDEAYA Biosciences Inc. stockFree Investment Portfolio Suggestions - Autocar Professional
IDEAYA Biosciences: Precision Oncology Pipeline and Synthetic Lethality Catalysts - AInvest
IDEAYA's First-in-Class Cancer Pipeline: Major Clinical Updates Coming at 10th Anniversary R&D Day - Stock Titan
Signaturefd LLC Increases Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC - The Malaysian Reserve
Is IDEAYA Biosciences Inc. a good long term investmentRobust financial gains - jammulinksnews.com
IDEAYA Biosciences Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com
Breakthrough Lung Cancer Drug IDE849 Shows First Human Results: 70+ Patient Data Coming at WCLC 2025 - Stock Titan
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA Biosciences: TD Cowen initiates coverage with Buy rating. - AInvest
Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences - TipRanks
TD Cowen initiates Ideaya Biosciences stock with Buy rating By Investing.com - Investing.com Canada
autocarpro> 2025> What analysts say about IDEAYA Biosciences Inc. stockPhenomenal trading returns - Autocar Professional
IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan
Teacher Retirement System of Texas Cuts Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
(IDYA) Proactive Strategies - news.stocktradersdaily.com
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionROI Driven Alerts - Newser
How IDEAYA Biosciences Inc. stock performs during market volatilityDaily Stock Radar - Newser
Brokerages Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Target Price at $47.55 - Defense World
The Goldman Sachs Group Upgrades IDEAYA Biosciences (NASDAQ:IDYA) to “Hold” - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Stock Rating Upgraded by Royal Bank Of Canada - Defense World
Ideaya Biosciences stock gets Neutral rating from Goldman Sachs By Investing.com - Investing.com Canada
Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital - MSN
Ideaya Biosciences shares fall 2.68% intraday as Biocytogen Pharmaceuticals enters into a global licensing agreement with BeOne Medicines. - AInvest
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences stock price target lowered to $30 by RBC Capital - Investing.com Canada
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):